These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17593135)

  • 1. Intestinal permeability and irritable bowel syndrome.
    Camilleri M; Gorman H
    Neurogastroenterol Motil; 2007 Jul; 19(7):545-52. PubMed ID: 17593135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
    Barbara G
    Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.
    Piche T; Barbara G; Aubert P; Bruley des Varannes S; Dainese R; Nano JL; Cremon C; Stanghellini V; De Giorgio R; Galmiche JP; Neunlist M
    Gut; 2009 Feb; 58(2):196-201. PubMed ID: 18824556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alterations of intestinal epithelial barrier and flora in the irritable bowel syndrome].
    Piche T
    Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S40-7. PubMed ID: 19303538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
    Camilleri M; Lasch K; Zhou W
    Am J Physiol Gastrointest Liver Physiol; 2012 Oct; 303(7):G775-85. PubMed ID: 22837345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario.
    Marshall JK; Thabane M; Garg AX; Clark W; Meddings J; Collins SM;
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1317-22. PubMed ID: 15606393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
    Camilleri M
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
    Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC; Dong L; Wang Y; Wang SH; Cao MB
    Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
    Kerckhoffs AP; Ter Linde JJ; Akkermans LM; Samsom M
    Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of microRNA in IBS with increased gut permeability.
    Vicario M; Martínez C; Santos J
    Gut; 2010 Jun; 59(6):710-2. PubMed ID: 20551452
    [No Abstract]   [Full Text] [Related]  

  • 13. Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease.
    Olbe L
    Scand J Gastroenterol; 2008; 43(2):234-41. PubMed ID: 17918000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
    Grover M; Herfarth H; Drossman DA
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):48-53. PubMed ID: 18848909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and complementary approaches for the treatment of irritable bowel syndrome.
    Wald A; Rakel D
    Nutr Clin Pract; 2008; 23(3):284-92. PubMed ID: 18595861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: probiotics and prebiotics in irritable bowel syndrome.
    Spiller R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments targeting putative mechanisms in irritable bowel syndrome.
    Cremonini F; Talley NJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):82-8. PubMed ID: 16265125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postinfectious irritable bowel syndrome.
    DuPont AW
    Clin Infect Dis; 2008 Feb; 46(4):594-9. PubMed ID: 18205536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.